Welcome to our dedicated page for Scynexis news (Ticker: SCYX), a resource for investors and traders seeking the latest updates and insights on Scynexis stock.
SCYNEXIS, Inc. develops therapies for severe rare diseases and difficult-to-treat fungal infections. The company’s updates center on SCY-770, a clinical-stage oral direct AMPK activator for autosomal dominant polycystic kidney disease, and SCY-247, a second-generation triterpenoid antifungal therapy in development for invasive candidiasis and prophylaxis of invasive fungal disease.
SCYNEXIS news also covers its fungerp antifungal platform, FDA designations for SCY-247, scientific presentations, financial results, and corporate actions. The company has licensed ibrexafungerp, including BREXAFEMME® for vulvovaginal candidiasis and reduction in recurrent vulvovaginal candidiasis, to GSK, making collaboration and license-agreement updates a recurring disclosure theme.
SCYNEXIS (NASDAQ:SCYX) reported Q1 2026 results and a major pipeline expansion. The company acquired SCY-770, an oral AMPK activator for ADPKD with FDA Orphan Drug designation, and plans a Phase 2 study starting Q4 2026 with early efficacy data expected in H2 2027.
SCYNEXIS advanced antifungal SCY-247, completed oral Phase 1, began IV Phase 1 dosing, and opened an expanded access program. A March private placement delivered about $37.2 million net, supporting a cash runway to mid-2029. GSK’s planned BREXAFEMME relaunch could generate up to approximately $146 million in annual net sales milestones.
SCYNEXIS (Nasdaq: SCYX) announced inducement equity awards approved April 30, 2026 for a newly hired Vice President. The grants include stock options for 125,000 shares at an exercise price of $0.93 and 20,000 RSUs.
Options vest over four years starting April 13, 2026; RSUs vest in three equal annual installments beginning June 15, 2026. Awards were granted under the company’s 2015 Inducement Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Poxel sold clinical-stage AMPK activator PXL770 (to be renamed SCY-770) to Scynexis (NASDAQ: SCYX) for total consideration of up to $196 million, including an $8 million upfront payment and up to $188 million in milestone payments. PXL770 holds FDA orphan drug designation and patent protection through at least 2041. A Phase 2 ADPKD proof-of-concept study is expected to start in Q4 2026 with a first efficacy readout in H2 2027. IPF will receive 75% of proceeds to repay debt, with limited amounts retained for Poxel liquidity.
SCYNEXIS (NASDAQ: SCYX) entered a private placement expected to close on or about April 1, 2026, generating approximately $40.0 million upfront and up to $52.2 million more if Common Warrants are fully exercised, subject to stockholder approval.
The company will issue 34,750,000 common shares, 8,750,000 pre-funded warrants and accompanying Common Warrants for an aggregate of 43,500,000 warrants; combined prices were $0.92 and $0.9199. The financing extends cash runway into mid-2029 and includes institutional investors and CEO participation.
SCYNEXIS (NASDAQ: SCYX) completed a transformative asset acquisition of PXL-770 (now SCY-770), a clinical-stage oral, selective direct AMPK activator for autosomal dominant polycystic kidney disease (ADPKD). The company will pursue a Phase 2 proof-of-concept study beginning in Q4 2026, with an early efficacy readout expected in H2 2027. SCY-770 has U.S. FDA Orphan Drug Designation. Transaction terms include an $8 million upfront payment plus up to $8 million in development milestones and up to $180 million in commercial milestones.
SCYNEXIS (NASDAQ: SCYX) reported full-year 2025 results and a corporate update highlighting a $24.8M one-time payment from GSK, year-end cash, cash equivalents and investments of $56.3M and a cash runway of more than two years. The company advanced SCY-247, began IV dosing (topline data H2 2026), plans an expanded access program H1 2026, and received QIDP and Fast Track designations.
Full-year 2025 revenue totaled $20.6M versus $3.7M in 2024; R&D expense fell 15.6% to $22.3M.
SCYNEXIS (NASDAQ: SCYX) announced dosing of first participants in a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of intravenous SCY-247 for invasive candidiasis and prophylaxis against invasive fungal disease. FDA QIDP and Fast Track designations were previously granted. Results from the IV trial are expected in 2026. The company noted positive SAD/MAD oral SCY-247 data in September 2025 showing target exposures at lower doses and is exploring non-dilutive funding to support the program.
SCYNEXIS (NASDAQ: SCYX) announced presentations on its second‑generation fungerp, SCY-247, at the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI), Jan 28–30, 2026, in Las Vegas.
The company said SCY-247 showed potent in vitro and in vivo antifungal activity, a favorable safety profile, and supportive pharmacokinetics in clinical investigations to date. Oral presentation: Jan 29, 9:00–10:30am; poster: Jan 30. Materials will be posted in the company’s Publications and Presentations section after the meeting.
SCYNEXIS (NASDAQ: SCYX) announced that the U.S. FDA granted QIDP and Fast Track designations for its second‑generation triterpenoid antifungal, SCY-247. The company noted QIDP will provide at least 10 years of post‑approval market exclusivity and Fast Track may enable more frequent FDA interaction, rolling review, and eligibility for accelerated approval or priority review. SCYNEXIS plans to initiate a Phase 1 IV study and a Phase 2 oral study in invasive candidiasis in 2026, and aims to release oral proof‑of‑concept data the same year. SCY-247 has shown preclinical activity against multi‑drug resistant fungi including Candida auris and azole‑resistant Aspergillus.
SCYNEXIS (NASDAQ: SCYX) received a 180-calendar-day extension from Nasdaq to regain compliance with the minimum bid price rule, extending the cure period to June 15, 2026.
Nasdaq confirmed SCYNEXIS meets other continued listing criteria and the company said it may use a reverse stock split if needed. Management also confirmed plans to complete a Phase 1 IV study and seek proof-of-concept Phase 2 oral data for investigational antifungal SCY-247 in invasive candidiasis, while maintaining commitments to regain full Nasdaq compliance.